Vertex pharma announces positive phase 3 study results for trikafta

Positive phase 3 study results for trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in people ages 12 and older with cystic fibrosis who have one copy of the f508del mutation and one gating or residual function mutation.vertex pharmaceuticals inc - phase 3 study met primary endpoint and all secondary endpoints.vertex pharmaceuticals inc - study is a u.s. post-marketing commitment and will be submitted to fda.vertex - data will be submitted to ema to support indication expansion of eu label following triple combination approval.
VRTX Ratings Summary
VRTX Quant Ranking